Results 241 to 250 of about 26,612 (257)

The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis

Expert Opinion on Pharmacotherapy, 2013
Masanori Abe, Kazuyoshi Okada, Noriaki Maruyama   +2 more
exaly  

Synthesis of a Dipeptidyl Peptidase 4 Inhibitor

Synfacts, 2009
openaire   +1 more source

Ameliorating effect of the novel dipeptidyl peptidase‐4 inhibitor teneligliptin on psoriasis: A report of two cases

Journal of Dermatology, 2015
, Hiroshi Nagai, Chikako Nishigori
exaly  

Synthesis of a Dipeptidyl Peptidase-4 Inhibitor

Synfacts, 2019
openaire   +1 more source

Dipeptidyl Peptidase‐4 Inhibitor Anagliptin Prevents Intracranial Aneurysm Growth by Suppressing Macrophage Infiltration and Activation

Journal of the American Heart Association, 2017
Sei Higuchi, Hiroharu Kataoka, Manabu Nagata   +2 more
exaly  

Dipeptidyl Peptidase-4 Inhibitor Induced Angioedema - An Overlooked Adverse Drug Reaction?

Current Diabetes Reviews, 2018
Christian Von Buchwald, Lise Aagaard
exaly  

Dipeptidyl peptidase-4 inhibitors/metformin

Reactions Weekly, 2018
openaire   +1 more source

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

Current Medical Research and Opinion, 2009
Richard Pratley
exaly  

Evogliptin: a new dipeptidyl peptidase inhibitor for the treatment of type 2 diabetes

Expert Opinion on Pharmacotherapy, 2016
exaly  

Dipeptidyl Peptidase 4 Inhibitor Sitagliptin Protects Endothelial Function in Hypertension Through a Glucagon–Like Peptide 1–Dependent Mechanism

Hypertension, 2012
Yi-Xiang Wang, Aimin Xu, Xiaoqiang Yao   +2 more
exaly